A median overall survival of 13.2 months against 6.7 months for chemotherapy is the kind of gap that reshapes a disease category, and Revolution Medicines is now sprinting to translate that Phase 3 result into an actual approved product before competitors can close in on RAS-mutant pancreatic cancer. The FDA has accepted the New Drug Application for daraxonrasib in previously treated metastatic pancreatic adenocarcinoma, a filing that followed RASolute 302 data published simultaneously in the New England Journal of Medicine and presented at ASCO’s Plenary Session, the kind of dual debut that signals scientific confidence as much as strategic timing. The trial hit both dual primary endpoints, overall survival and progression-free survival, plus patient-reported quality of life measures over chemotherapy, with a safety profile the company describes as manageable.
The company is not waiting for approval to establish clinical presence. An Expanded Access Program, cleared by the FDA and opened in May, distributed daraxonrasib to physicians treating more than 2,000 patients within weeks of launch, reaching academic centers and community practices across nearly every U.S. state and Puerto Rico. That scale of pre-approval distribution does two things simultaneously: it generates real-world safety exposure that regulators will watch, and it builds the prescriber familiarity that commercial teams spend months trying to create after an approval. The EMA has also initiated a phased review of daraxonrasib under its Cancer Medicines Pathfinder project, evaluating sections of the dossier as they become available rather than waiting for a complete Marketing Authorization Application, a structural acceleration that compresses the European path without requiring Revolution to hold data back.
Beyond pancreatic cancer, the pipeline logic is expanding fast. The FDA granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic NSCLC harboring KRAS mutations other than G12C, a population where prior platinum-based chemotherapy and anti-PD-(L)1 therapy have already failed. Enrollment in the Phase 3 RASolve 301 trial is expected to complete this year, with an initial readout projected for 2027. Separately, new combination data for zoldonrasib, the company’s G12D-selective covalent inhibitor, showed preliminary activity in first-line PDAC alongside chemotherapy and in a novel doublet pairing with daraxonrasib in previously treated G12D disease. Both combinations now have global Phase 3 trials running, RASolute 305 and RASolute 309 respectively.
The single variable that determines whether Revolution’s aggressive commercial and regulatory posture pays off is the FDA’s action date on the daraxonrasib NDA. Approval timing will set the window for first-mover pricing and formulary positioning in second-line pancreatic cancer, and any complete response letter would reset the entire competitive clock for a company that has built its near-term value almost entirely around this one indication.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
